DelveInsight

pharma-news
Eli Lilly’s COVID-19 Antibody trial; Approval for Oriahnn; Gilead’s Remdesivir Clinic...

Eli Lilly and AbCellera announced the dosing of the patients suffering from COVID-19 with antibody candidate - LY-CoV555.  LY-CoV555 is a neutralizing IgG1 monoclonal antibody (mAb) t...


DelveInsight Logo
Introducing a new brand identity, and a new website: DelveInsight.

Today we’re unveiling a new identity and launching a new logo.  For any company, to get a new logo designed might look like a cakewalk; however, it is exactly the opposite. This is a big d...


Cholera vaccine delivered; Rice-inspired breakthroughs; International partnerships

Cholera vaccine delivered through a cup of rice water Vaccinations against prevalent pathogens could be ingested as oral or inhaled as nasal vaccines, this is due to the development of non-invasiv...


acute myeloid leukemia
Predicting risk of Acute Myeloid Leukemia (AML) in healthy individuals

The occurrence of acute myeloid leukemia (AML) keeps on increasing with age and mortality surpasses 90% if diagnosed after age of 65. Most cases emerge with no perceivable early side effects and pa...


transthyretin amyloidosis
Notizia

Arming antibiotics with a vaccination-like immune response Harnessing the ability of the body’s immune system has already well-tried to be effective in treating cancer. Marcos Pires, Ph.D., a Le...



enzymes FAAH
Fatty Acid Amide Hydrolase (FAAH) Inhibitor – an enzyme with novel therapeutic potential

Fatty acid amide hydrolase (FAAH) belongs to the serine hydrolase family of enzymes. The identification of this enzyme was led by the discovery and characterization of fatty acid amides, including ...


hepatic encephalopathy
Hepatic Encephalopathy- An ailment of liver to brain

Hepatic Encephalopathy (HE) can be described as deterioration of brain function occurring due to accumulation of toxic substances in the blood which ultimately reach the brain. People with long-st...


Default Blog Image
NF-κB Inhibitors- A Promising Future

NF-κB (Nuclear Factor kappa-light-chain-enhancer of activated B cells) is a protein transcription factor that can orchestrate complex biological processes such as cell survival, cytokine production...


transthyretin amyloidosis
Idera’s drug; CRISPR increase risk; Juvenescence grabbed USD 50M; AstraZeneca, Lilly termin...

Idera's dermatomyositis drug missed primary endpoint in phase 2 Idera’s toll-like receptor (TLR) antagonist, IMO-8400, failed to meet its primary endpoint in a phase 2 trial carried on adults with ...


Editor's Pick
Which Pipeline Therapy Has The Potential To Revolutionize The Dystrophic Epid...

Dystrophic epidermolysis bullosa (DEB) is a common skin disease with a chronic history ...

Can FcRn Antagonists Be The Game-Changer in the Generalized Myasthenia Gravis...

Though a rare disease, generalized myasthenia gravis (gMG) still affects around 60,000 ...

Exploring Potential New Avenues for Bronchopulmonary Dysplasia Treatment

Bronchopulmonary Dysplasia is the most common long-term respiratory morbidity of low-we...

A Market Space Beyond Lucentis and Eylea for Retinal Vein Occlusion Treatment

Competitive inroads by Regeneron’s Eylea in the retinal vein occlusion treatment landsc...

NexoBrid and its Awaiting US Approval

A Burn takes place when the skin comes into contact with a heat source. Burns can occur...

ASCO Conference 2022
ASCO Conference 2022

The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.